Viking Therapeutics (VKTX) Accounts Payables (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Accounts Payables data on file, last reported at $67.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 772.28% year-over-year to $67.2 million; the trailing twelve-month figure through Mar 2026 stood at $67.2 million (up 772.28% YoY), and the FY2025 full-year result was $53.3 million, up 442.66% from the prior year.
• Accounts Payables advanced to $67.2 million in Q1 2026, from $53.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $67.2 million in Q1 2026 to a low of $254000.0 in Q3 2024.
• A 5-year average of $12.2 million and a median of $5.7 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables slumped 95.55% in 2024 and surged 1637.4% in 2025, its largest moves.
• Tracing VKTX's Accounts Payables over 5 years: stood at $8.5 million in 2022, then decreased by 11.92% to $7.5 million in 2023, then surged by 30.63% to $9.8 million in 2024, then surged by 442.66% to $53.3 million in 2025, then increased by 26.16% to $67.2 million in 2026.
• Business Quant data shows VKTX's Accounts Payables at $67.2 million in Q1 2026, $53.3 million in Q4 2025, and $4.4 million in Q3 2025.